Trident Medical Center announced that it will participate with Sarah Cannon, the Cancer Institute of HCA Healthcare, in a study called STRIVE, which focuses on developing a test for early cancer detection. The STRIVE Study is designed to determine if a blood test can complement mammography screenings by identifying genomic material arising from tumors to help discover breast and other cancers at their earliest stages.
“Today’s announcement marks a major milestone in Trident’s commitment to women’s health,” said radiologist Brian Burke, MD, who will serve as the study’s lead on-site physician. “We hope the study participants from the Lowcountry and around the United States will one day soon be able to say, ‘I made a difference.’”
The study, sponsored by GRAIL, Inc., is seeking to enroll 120,000 women across participating sites. Women who volunteer to participate will provide a blood sample and complete a short questionnaire at the time of their regular screening mammogram. In addition, participants will be followed and their health records will be monitored for up to five years for new cancer diagnoses.
“By participating in this exciting research effort, women in South Carolina’s Lowcountry will join other women around the country to help GRAIL scientists in their efforts to develop a test that is intended to enhance our ability to detect cancer at earlier and more treatable stages,” said Dax Kurbegov, MD, principal investigator of the STRIVE Study at Sarah Cannon and Vice President and Physician-in-Chief of Clinical Programs for Sarah Cannon. “The study is designed to help develop a test that can identify tiny fragments of genomic material that may signal the presence of breast or other cancers.”
The study is being offered to women undergoing screening mammograms at several Sarah Cannon locations, including Trident Medical Center. For more information on the STRIVE Study, to see the list of participating sites or to learn if you might be eligible to join, women can visit JoinSTRIVE.com, email STRIVE@sarahcannon.com or call 1-833-I-STRIVE (833-478-7483).
About Trident Medical Center
For more than 40 years staff and physicians at Trident Health have provided acute healthcare services to families in South Carolina’s Lowcountry. Services are provided through its two hospitals, Trident Medical Center and Summerville Medical Center; two freestanding emergency departments, Moncks Corner Medical Center and Centre Pointe Emergency; and two urgent care centers, CareNow Urgent Care Goose Creek and CareNow Urgent Care North Charleston. Both hospitals have received top ranking as Joint Commission Top Hospitals for Quality Performance and are Joint Commission Certified for Advanced Heart Failure and Advanced Primary Stroke Centers. Trident Health is one of the South Carolina Lowcountry’s largest employers with more than 2,500 employees and has a medical staff of nearly 500 physicians. In 2017 it provided $47.6 million in uncompensated care and paid $35.5 million in local, state and federal taxes. To learn more about how Trident Health is growing to meet the needs of our growing region and how to join our team go to www.tridenthealthsystem.com.
About Sarah Cannon
Sarah Cannon, the Cancer Institute of HCA Healthcare, offers integrated cancer services with convenient access to cutting-edge therapies for those facing cancer in communities across the United States and United Kingdom. Sarah Cannon’s cancer programs include individualized patient navigation provided by oncology-trained nurses, more than 1,000 stem cell transplants performed annually throughout the Sarah Cannon Blood Cancer Network, hundreds of clinical trials, and molecular profiling capabilities. Through its services, Sarah Cannon is providing state-of-the-art cancer care close to home for hundreds of thousands of patients, a number unmatched by any single cancer center. To learn more about Sarah Cannon, visit sarahcannon.com.
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products for the early detection of cancer. The company is located in Menlo Park, California and Hong Kong. It is supported by leading global investors and pharmaceutical, technology and healthcare companies. For more information, please visit www.grail.com.